Acviss: The AI-Powered Counterfeit Defense Pharma Needs Across Every Pack and Supply Chain

Acviss is an online brand-protection and counterfeit-enforcement platform that combines product serialisation and authentication with AI-enabled digital monitoring to help identify suspected counterfeit medicines, unauthorised sellers, and fraudulent brand activity. Its Truviss platform analyses marketplace, website, social-media, domain, image, text, and seller-behaviour signals, while product-level verification data can add context to investigations.

Counterfeit pharmaceuticals create a dual operational problem: teams need to investigate physical products and supply-chain anomalies while also responding to rapidly changing online listings, imitation sites, and seller networks. Acviss brings scan activity, secure product identifiers, traceability information, and web-monitoring signals into a more connected intelligence workflow, using machine learning and computer-vision methods to identify anomalies and correlate related activity across channels.

For pharmaceutical operations, this can reduce the manual effort involved in locating, reviewing, and prioritising large volumes of potential infringements. Centralised evidence and risk signals can help teams investigate suspected incidents sooner, focus enforcement activity on higher-priority cases, and build a clearer picture of where counterfeit or diversion risks may be emerging across physical and digital distribution channels.

Last checked on August 25, 2026: Acviss continues to present an AI-supported pharmaceutical anti-counterfeiting suite combining authentication, traceability, and Truviss online market surveillance.

What is Acviss?

Acviss is a pharmaceutical anti-counterfeiting and online brand-protection platform that supports product serialisation, authentication, supply-chain traceability, and monitoring of suspected counterfeit or unauthorised online listings. It is designed for pharmaceutical manufacturers and their quality, supply-chain, brand-protection, legal, and operations functions; its platform combines 2D identifiers, scan events, blockchain-based chain-of-custody records, and AI-supported market surveillance through its Certify, Origin, and Truviss products.

Acviss states that its products support DSCSA data elements and EPCIS logging, EMVS-compatible serialisation-data export, and documentation workflows associated with EU FMD, CDSCO, WHO-GMP, and PIC/S requirements; buyers should independently validate these claims for their intended deployment.

Why Do Leading Healthcare Teams Trust Acviss?

• Acviss states that its infrastructure is ISO 27001 certified, a relevant information-security control for deployments handling authentication, traceability, and scan-event data.

• Acviss describes its Origin product as providing pharmaceutical serialisation and chain-of-custody records intended to support CDSCO audit-readiness workflows.

• Acviss states that its traceability tooling can be configured around CDSCO requirements and produces batch, sourcing, and chain-of-custody records.

• The company describes its traceability platform as GS1-compatible and able to generate EPCIS event data, which can matter for supply-chain data interoperability assessments.

• Acviss reports two granted patents on its India traceability offering; the reviewed source does not identify the patent jurisdictions or claims.

• Acviss was named among the NASSCOM DeepTech Emerge 50 Award winners for 2026, selected from a reported 750 applications.

• Acviss’s pharmaceutical offering combines product-level authentication, traceability, and online market surveillance, rather than relying solely on digital listing monitoring.

• Acviss states that it uses blockchain-backed digital identities and records supply-chain events from manufacturing to point of sale; independent technical validation was not identified in the reviewed sources.

• Acviss reports that consumer personal data in its scan-based programs is encrypted at rest and in transit, with consent-based restrictions on third-party sharing; this claim relates to its Southeast Asia offering rather than a pharmaceutical-specific privacy policy.

• FDA clearance, CE marking, HIPAA alignment, and healthcare-specific clinical validation were not specified in the reviewed sources.